Neha Motwani Joins Longeveron Board

Longeveron Inc. (NASDAQ: LGVN), a biotechnology company in the clinical stage of developing regenerative medicines for serious and chronic aging-related conditions, has announced the election of Neha Motwani to its Board of Directors. This decision was made during the Company’s Annual Meeting of Stockholders held recently.

Neha Motwani brings a wealth of experience from the healthcare investment banking sector, having served over 25 years in various roles. She most recently held the position of Managing Director at William Blair in their Healthcare Investment Banking division. Her career includes significant roles at Truist Securities, Oppenheimer and Company, Stifel Financial, and Cowen and Company. Throughout her career, she has successfully managed transactions that raised approximately $7.0 billion. Ms. Motwani holds a B.A. in political science from Columbia University.

Expressing his enthusiasm for the new board member, Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron, stated, “I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the Board of Directors. Her extensive knowledge of biopharma company operations, financing and capital markets will bring significant value to Longeveron as we continue to advance Lomecel-B™, our proprietary, scalable, allogeneic cellular therapy. With five positive clinical trials across three indications, we believe Lomecel-B™ has the potential to be an important therapy for some of the most difficult diseases and conditions associated with aging.”

Ms. Motwani also expressed her excitement about joining Longeveron’s Board of Directors. “I am delighted to join the Board of Directors of Longeveron at this exciting phase of the Company’s clinical development,” she said. “I look forward to working with this talented team to continue their mission to advance their novel cellular therapy, Lomecel-B™, for the potential treatment of HLHS, a rare and devastating congenital heart condition, and diseases of the aging.”

Longeveron is a clinical stage biotechnology company that focuses on developing regenerative medicines to address unmet medical needs. The company’s leading investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell (MSC) therapy derived from the bone marrow of young, healthy adult donors. Lomecel-B™ has various potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects. Its broad potential applications span a diverse range of disease areas.

Currently, Longeveron is pursuing three primary indications for Lomecel-B™: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. The Lomecel-B™ HLHS program has garnered three important FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation.

Longeveron’s efforts to advance Lomecel-B™ are bolstered by the strong leadership and strategic vision contributed by its Board of Directors, now enhanced by the inclusion of Neha Motwani. The company remains focused on its mission to provide effective treatments for some of the most challenging aging-related conditions.